Lau Associates LLC cut its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.4% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 12,277 shares of the company’s stock after selling 560 shares during the quarter. IDEXX Laboratories accounts for 1.7% of Lau Associates LLC’s portfolio, making the stock its 12th largest position. Lau Associates LLC’s holdings in IDEXX Laboratories were worth $3,065,000 at the end of the most recent quarter.
Other hedge funds have also recently modified their holdings of the company. Rehmann Capital Advisory Group grew its holdings in shares of IDEXX Laboratories by 44.9% in the 2nd quarter. Rehmann Capital Advisory Group now owns 668 shares of the company’s stock worth $146,000 after acquiring an additional 207 shares during the last quarter. Bbva Compass Bancshares Inc. grew its holdings in shares of IDEXX Laboratories by 11.7% in the 2nd quarter. Bbva Compass Bancshares Inc. now owns 2,264 shares of the company’s stock worth $493,000 after acquiring an additional 237 shares during the last quarter. Fiera Capital Corp grew its holdings in shares of IDEXX Laboratories by 2.6% in the 2nd quarter. Fiera Capital Corp now owns 9,775 shares of the company’s stock worth $2,130,000 after acquiring an additional 249 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of IDEXX Laboratories by 1.3% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 22,160 shares of the company’s stock worth $4,830,000 after acquiring an additional 284 shares during the last quarter. Finally, Eads & Heald Wealth Management grew its holdings in shares of IDEXX Laboratories by 5.7% in the 2nd quarter. Eads & Heald Wealth Management now owns 7,331 shares of the company’s stock worth $1,598,000 after acquiring an additional 393 shares during the last quarter. Institutional investors own 91.22% of the company’s stock.
A number of equities analysts recently issued reports on the company. Zacks Investment Research upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $255.00 target price on the stock in a report on Monday, June 18th. Piper Jaffray Companies lifted their target price on IDEXX Laboratories to $236.00 and gave the stock an “overweight” rating in a report on Wednesday, August 1st. BidaskClub raised IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 15th. Credit Suisse Group raised their target price on IDEXX Laboratories from $228.00 to $231.00 and gave the stock an “outperform” rating in a research report on Thursday, June 21st. Finally, Stifel Nicolaus raised their target price on IDEXX Laboratories from $225.00 to $260.00 and gave the stock a “buy” rating in a research report on Tuesday, July 10th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company’s stock. IDEXX Laboratories presently has an average rating of “Buy” and a consensus target price of $244.00.
In related news, VP Jacqueline Studer sold 8,598 shares of IDEXX Laboratories stock in a transaction on Monday, August 6th. The stock was sold at an average price of $242.37, for a total transaction of $2,083,897.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bruce L. Claflin acquired 415 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, August 3rd. The shares were purchased at an average cost of $242.12 per share, with a total value of $100,479.80. Following the transaction, the director now owns 1,415 shares of the company’s stock, valued at approximately $342,599.80. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 70,129 shares of company stock valued at $17,159,219. 2.56% of the stock is currently owned by insiders.
Shares of IDEXX Laboratories stock traded up $8.35 during midday trading on Friday, hitting $222.46. The company’s stock had a trading volume of 55,558 shares, compared to its average volume of 487,884. The stock has a market cap of $21.62 billion, a PE ratio of 67.21, a price-to-earnings-growth ratio of 2.28 and a beta of 0.64. The company has a quick ratio of 0.73, a current ratio of 0.96 and a debt-to-equity ratio of -14.77. IDEXX Laboratories, Inc. has a 1-year low of $146.09 and a 1-year high of $256.22.
IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Wednesday, August 1st. The company reported $1.23 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.17 by $0.06. The business had revenue of $580.75 million during the quarter, compared to analysts’ expectations of $574.68 million. IDEXX Laboratories had a negative return on equity of 703.80% and a net margin of 14.50%. IDEXX Laboratories’s revenue was up 14.1% compared to the same quarter last year. During the same quarter last year, the firm posted $0.87 earnings per share. Analysts expect that IDEXX Laboratories, Inc. will post 4.18 EPS for the current fiscal year.
IDEXX Laboratories Profile
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Read More: What factors cause inflation to rise?
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.